Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60

Obstetrics and Gynecology

Volumn 95, Issue 1, 2000, Pages 104-110

  Cohen, Fredric J ^a   Watts, Steven ^a   Shah, Aarti ^a   Akers, Robin ^a   Plouffe Jr , Leo ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RALOXIFENE;

ADULT; AGE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSVAGINAL ECHOGRAPHY; VAGINA BLEEDING;

ENDOMETRIUM; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; UTERUS;

EID: 0033989737     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(99)00554-2     Document Type: Article

References (31)

1. Mitlak B.H., Cohen F.J. Selective estrogen receptor modulators A look ahead . Drugs. 57:1999;653-663.
2. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 337:1997;1641-1647.
3. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators . JAMA. 282:1999;637-645.
4. Cummings S., Eckert S., Krueger K., Grady D., Powles T., Cauley J., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA. 281:1999;2189-2197.
5. Walsh B.W., Kuller L.H., Wild R.A., Paul S., Farmer M., Lawrence J.B., et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 279:1998;1445-1451.
6. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 275:1996;370-375.
7. Grady D., Gebretsadik T., Kerlikowske K., Ernster V., Petitti D. Hormone replacement therapy and endometrial cancer risk A metaanalysis . Obstet Gynecol. 85:1995;304-313.
8. Ke H.Z., Chen H.K., Simmons H.A., Qi H., Crawford D.T., Pirie C.M., et al. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone. 20:1997;31-39.
9. Medlock K.L., Branham W.S., Sheehan D.M. Effects of toremifene on neonatal rat uterine growth and differentiation. Biol Reprod. 56:1997;1239-1244.
10. Tomas E., Kauppila A., Blanco G., Apaja-Sarkkinen M., Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol. 59:1995;261-266.
11. Lindahl B., Andolf E., Ingvar C., Liedman R., Ranstam J., Willen R. Endometrial thickness and ovarian cysts as measured by ultrasound in asymptomatic postmenopausal breast cancer patients on various adjuvant treatments including tamoxifen. Anticancer Res. 17:1997;3821-3824.
12. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study . J Natl Cancer Inst. 90:1998;1371-1388.
13. Sato M., Rippy M.K., Bryant H.U. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 10:1996;905-912.
14. Bjarnason N.H., Haarbo J., Byrjalsen I., Kauffman R.F., Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation. 96:1997;1964-1969.
15. Lufkin E.G., Whitaker M.D., Nickelsen T., Argueta R., Caplan R.H., Knickerbocker R.K., et al. Treatment of established postmenopausal osteoporosis with raloxifene A randomized trial . J Bone Miner Res. 13:1998;1747-1754.
16. Kurman R.J., Norris H.J. Kurman R.J. Blaustein's pathology of the female genital tract. 1994;411-427 Springer-Verlag, New York.
17. Langer R.D., Pierce J.J., O'Hanlan K.A., Johnson S.R., Espeland M.A., Trabal J.F., et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. N Engl J Med. 337:1997;1792-1798.
18. Davies GC, Huster WJ, Shen W, Mitlak BH, Plouffe L, Shah A, et al. The endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause. In press.
19. Sener A.B., Seckin N.C., Ozmen S., Gokmen O., Dogu N., Ekici E. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil Steril. 65:1996;354-357.
20. McGonigle K.F., Shaw S.L., Vasilev S.A., Odom-Maryon T., Roy S., Simpson J.F. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol. 178:1998;1145-1150.
21. Nuovo M.A., Nuovo G.J., McCaffrey R.M., Levine R.U., Barron B., Winkler B. Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol. 8:1989;125-131.
22. Corley D., Rowe J., Curtis M.T., Hogan W.M., Noumoff J.S., Livolsi V.A. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol. 79:1992;111-116.
23. Kennedy M.M., Baigrie C.F., Manek S. Tamoxifen and the endometrium Review of 102 cases and comparison with HRT-related and non-HRT-related endometrial pathology . [in process citation] Int J Gynecol Pathol. 18:1999;130-137.
24. Lorrain J., Ravnikar V.A., Charest N. Compliance with menopausal hormone replacement therapy. Lorrain J., Plouffe L. Jr, Ravnikar V.A., Speroff L., Watts N. Comprehensive management of menopause. 1994;229-245 Springer-Verlag, New York.
25. Iatrakis G., Diakakis I., Kourounis G., Sakellaropoulos G., Rammos G., Ladopoulos J., et al. Postmenopausal uterine bleeding. Clin Exp Obstet Gynecol. 24:1997;157.
26. Archer D.F., Pickar J.H., Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. The Menopause Study Group. Obstet Gynecol. 83:1994;686-692.
27. Ettinger B., Li D.K., Klein R. Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy Comparison of cyclic versus continuous combined schedules . Fertil Steril. 69:1998;865-869.
28. Ettinger B., Pressman A., Bradley C. Comparison of continuation of postmenopausal hormone replacement therapy Transdermal versus oral estrogen . Menopause. 5:1998;152-156.
29. Hahn R.G. Compliance considerations with estrogen replacement Withdrawal bleeding and other factors . Am J Obstet Gynecol. 161:1989;1854-1858.
30. Hayes D.F., Van Zyl J.A., Hacking A., Goedhals L., Bezwoda W.R., Mailliard J.A., et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 13:1995;2556-2566.
31. Powles T., Eeles R., Ashley S., Easton D., Chang J., Dowsett M., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 352:1998;98-101.